Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  DaVita Inc.    DVA


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

DAVITA INC. : Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
05/26/2020 | 08:36am EDT

Item 8.01. Other Events.

On May 26, 2020, DaVita Inc. (the "Company") issued a press release, made pursuant to Rule 135c promulgated under the Securities Act of 1933, as amended, announcing the commencement of a private offering, subject to market and other conditions, of $1.75 billion aggregate principal amount of its Senior Notes due 2030 (the "2030 Notes"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Prior to the closing date of this offering, the Company will deliver a notice of its election to redeem all $1.75 billion aggregate principal amount outstanding of its 5.125% Senior Notes due 2024 (CUSIP No. 23918K AQ1; ISIN No. US23918KAQ13) (the "2024 Notes") on July 15, 2020 (the "Redemption Date"), conditioned upon the completion of the 2030 Notes offering. Pursuant to such notice, and conditioned upon the completion of the 2030 Notes offering, all of the outstanding 2024 Notes will be redeemed at a redemption price of 101.708% of the principal amount thereof plus accrued and unpaid interest to, but excluding, the Redemption Date in accordance with the terms of the Indenture, dated as of June 13, 2014, as supplemented, among the Company, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as trustee. The Company intends to use the net proceeds from the 2030 Notes offering referred to above, together with cash on hand, to finance the redemption of the 2024 Notes and pay all fees and expenses related to such redemption and the offering.

This Current Report on Form 8-K does not constitute a notice of redemption of the 2024 Notes. The CUSIP and ISIN numbers set forth above are included solely for informational purposes. The Company is not responsible for the use or selection of the CUSIP and ISIN numbers and no representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers set forth above. This Current Report on Form 8-K (and the exhibit hereto) shall not constitute an offer to sell or the solicitation of an offer to buy the 2030 Notes and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Number       Description
  99.1       Press Release dated May 26, 2020.
104.0        Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
Latest news on DAVITA INC.
06/17GILEAD SCIENCES : Javier Rodriguez Joins Gilead Sciences Board of Directors
06/17DAVITA KIDNEY CARE : Appoints Chief Nursing Officer
06/17DAVITA INC. : Change in Directors or Principal Officers (form 8-K)
06/09DAVITA INC. : Entry into a Material Definitive Agreement (form 8-K)
05/28NEPHROLOGY PRACTICE SOLUTIONS : Names New Chief Medical Officer
05/26DAVITA INC. : Announces Pricing of $1.75 Billion Senior Notes Offering
05/26DAVITA INC. : Other Events, Financial Statements and Exhibits (form 8-K)
05/26DAVITA INC. : Announces Offering of $1.75 Billion Senior Notes
05/20South Africa's Tiger Brands books $30 mln impairment on export businesses
05/07DAVITA : Continues to Support Teammates during COVID-19 Crisis
More news